ArticleWorld journal of surgical oncology2025
Mechanism of METTL14-mediated RAD21 mRNA epigenetic transcriptome modification in inhibiting thyroid cancer development.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The dual regulatory role of METTL14-mediated mFrontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigated the mechanism of methyltransferase-like 14 (METTL14)-mediated epigenetic transcriptome modification of RAD21 mRNA in inhibiting thyroid cancer (TC) development.
methodsTCGA and Starbase databases were used to predict the differential expression of METTL14 in TC tissues. First, 48 patients were enrolled. Immunohistochemistry, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and Western blot (WB) were employed for detecting METTL14 and RAD21 expression levels. The overall RNA N6-methyladenosine (m6A) methylation level was measured using m6A-RNA immunoprecipitation (MeRIP). TC cell lines were transfected with Ad-METTL14 and/or Ad-RAD21, and then detected for proliferation, apoptosis, migration, and invasion using cell count kit-8 assay, flow cytometry, and Transwell assay, respectively. MeRIP-qPCR was adopted to detect the RAD21 m6A modification level. RT-qPCR was applied for detecting RAD21 mRNA stability in actinomycin D-treated cells. RIP was implemented to detect METTL14-RAD21 interaction. Tumor formation assay was performed in nude mice. Tumor weight and volume were recorded. The collected tumor tissues were measured for Ki67-positive cell levels using immunohistochemistry, and METTL14 and RAD21 protein levels using WB.
resultsMETTL14 was notably downregulated and RAD21 was upregulated in TC tissues and cells. METTL14 overexpression inhibited TC cell proliferation, migration, and invasion, and promoted cell apoptosis. METTL14 overexpression reduced RAD21 mRNA stability and inhibited RAD21 expression through m6A modification. RAD21 upregulation caused opposite results to METTL14 overexpression on inhibiting TC cell malignant behaviors. METTL14 overexpression inhibited tumor formation in nude mice in vivo.
conclusionMETTL14 inhibits tumorigenesis in TC mice in vivo by mediating m6A modification of RAD21 and decreasing RAD21 mRNA stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.